This guy did say "my instinct tells me this is too good to be true".  And followed it by saying "there are very smart guys out there doing this study" and "I am doing the study".  "You never know...there is a good basis for it".

In a way, what he said sums up exactly what people who are PhDs in Molecular Biology tell me.  I asked a friend of mine who is a Business Development officer (and a PhD in Biology from NYU) for one of America's biggest pharma companies...and she said almost the same thing..."too good to be true".

As the Makalu report highlighted, RVX208 is essentially telling medical researchers that they have been doing research all wrong...you need a multi factorial drug to tackle a multifactorial disease like CVD.  What it tells me is that the response to a successful Phase 3 trial will exceed that to Amarin's results last year.